| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/04/2004 | US20040044013 Antiarthritic agents; side effect reduction |
| 03/04/2004 | US20040044011 2-Aminoalkyl-thieno[2,3-d]pyrimidines |
| 03/04/2004 | US20040044010 Central nervous system disorders; Alzheimer's disease; Parkinson's disease |
| 03/04/2004 | US20040044009 Drug abuse; cental nervous system disorders; cognition activators |
| 03/04/2004 | US20040044008 Dietetics; antilipemic agents; non-insulin dependent diabetes; cardiovascular disorders |
| 03/04/2004 | US20040044003 Therapeutic agents useful for treating pain |
| 03/04/2004 | US20040044002 Kinase inhibitors; antiproliferative agents; antiinflammatory agents; autoimmune diseases; skin disorders; anticancer agents; antiproliferative agents |
| 03/04/2004 | US20040044001 Use of II-1 inhibitors for treating II-1 mediated diseases |
| 03/04/2004 | US20040043999 Phthalazine derivatives as phosphodiesterase 4-inhibitors |
| 03/04/2004 | US20040043989 Therapy for drug resistant bacteria; topoisomerase inhibitor |
| 03/04/2004 | US20040043978 Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors |
| 03/04/2004 | US20040043976 16Alpha-methyl or ethyl substituted estrogens |
| 03/04/2004 | US20040043966 Using 1-hydroxy-2-(imidazolo(1,2-a)pyridin-3-yl)ethanediphosphonic acid; bone disorders |
| 03/04/2004 | US20040043962 Method for enhancing the effectiveness of cancer therapies |
| 03/04/2004 | US20040043927 Wound healing agents; anticancer agents; cardiovascular disorders |
| 03/04/2004 | US20040043926 Comprises polypeptides for diagnosing, treating and preventing cardiomyopathy, atherosclerosis and cancer |
| 03/04/2004 | US20040043919 Method for the treatment of neurological and neuropsychological disorders |
| 03/04/2004 | US20040043918 Containing phosphatides; killing cancer, tumor cells |
| 03/04/2004 | US20040043454 Growth arrest homeobox gene |
| 03/04/2004 | US20040043411 DSP-11 dual-specificity phosphatase |
| 03/04/2004 | US20040043402 Interferon-alpha induced gene |
| 03/04/2004 | US20040043074 Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
| 03/04/2004 | US20040043007 Transfection system |
| 03/04/2004 | US20040042990 Composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer, and use thereof |
| 03/04/2004 | US20040040909 Dispersion of carbon particles in high pressure water; conbustion gaseous mixture of hydrogen, oxygen |
| 03/04/2004 | CA2501719A1 Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 03/04/2004 | CA2496573A1 Agent for prevention and/or treatment of asthma |
| 03/04/2004 | CA2496572A1 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 03/04/2004 | CA2496464A1 Agent for prevention and/or treatment of itching |
| 03/04/2004 | CA2496268A1 Oligonucleotide tagged nucleoside triphosphates (otntps) for genetic analysis |
| 03/04/2004 | CA2496242A1 T-cell epitopes in staphylococcal enterotoxin b |
| 03/04/2004 | CA2496236A1 Preventives/remedies for cancer |
| 03/04/2004 | CA2496234A1 Salt-inducible kinases 2 and use thereof |
| 03/04/2004 | CA2495903A1 Novel biphenyl and biphenyl-like cannabinoids |
| 03/04/2004 | CA2495603A1 Benzonaphthyridines with pde 3/4 inhibiting activity |
| 03/04/2004 | CA2495597A1 Novel phenanthridines |
| 03/04/2004 | CA2495376A1 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 03/04/2004 | CA2495354A1 An agent for inhibiting articular cartilage extracellular matrix degradation |
| 03/04/2004 | CA2494953A1 Beta-lactamase inhibitor prodrug |
| 03/04/2004 | CA2494650A1 Pyridazinone-derivatives as pde4 inhibitors |
| 03/04/2004 | CA2494210A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 03/04/2004 | CA2494127A1 Pyrimido compounds having antiproliferative activity |
| 03/04/2004 | CA2493747A1 Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment |
| 03/03/2004 | EP1394175A1 Inhibitors of interleukin-1beta converting enzyme |
| 03/03/2004 | EP1394161A1 L−ASCORBIC ACID−2−O−MALEIC ACID−A−TOCOPHEROL DIESTER 1−PROPANOL ADDUCT AND PROCESS FOR PRODUCING THE SAME |
| 03/03/2004 | EP1394154A1 Five-membered heterocyclic alkanoic acid derivative |
| 03/03/2004 | EP1394152A1 2-iminoimidazole derivatives (1) |
| 03/03/2004 | EP1394150A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| 03/03/2004 | EP1394147A1 Carboxylic acid derivative and medicine comprising salt or ester of the same |
| 03/03/2004 | EP1393750A2 Conjugates for treating an immune disease |
| 03/03/2004 | EP1393739A1 Liver generation promoter |
| 03/03/2004 | EP1393736A1 Use of ginkgo biloba terpene free flavonoidic extract for oral hygiene, and composition containing such extract |
| 03/03/2004 | EP1393727A1 Remedial agent for myelopathic disease |
| 03/03/2004 | EP1393277A1 Use of nfkb inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1392850A2 Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
| 03/03/2004 | EP1392845A2 A g-protein coupled receptor and uses therefor |
| 03/03/2004 | EP1392844A2 Use of hmg fragments as anti-inflammatory agents |
| 03/03/2004 | EP1392830A2 Interleukin-18 mutants, their production and use |
| 03/03/2004 | EP1392720A2 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors |
| 03/03/2004 | EP1392713A2 Liver x receptor agonists |
| 03/03/2004 | EP1392702A1 Compounds and methods for inhibiting mrp1 |
| 03/03/2004 | EP1392699A1 6h-oxazolo 4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 03/03/2004 | EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 03/03/2004 | EP1392692A1 (oxo-pyrazolo 1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| 03/03/2004 | EP1392689A1 Tri- and tetraaza-acenaphthylen derivatives as crf receptor antagonists |
| 03/03/2004 | EP1392688A1 Pyrazino[1',2':1,6]pyrido[3,4-b]indole1,4-dione derivatives |
| 03/03/2004 | EP1392687A1 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| 03/03/2004 | EP1392685A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same |
| 03/03/2004 | EP1392683A1 SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF |
| 03/03/2004 | EP1392682A2 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 03/03/2004 | EP1392680A2 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 03/03/2004 | EP1392676A2 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| 03/03/2004 | EP1392674A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors |
| 03/03/2004 | EP1392666A1 Biologically active methylene blue derivatives |
| 03/03/2004 | EP1392663A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 03/03/2004 | EP1392662A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 03/03/2004 | EP1392661A1 Diarylurea derivatives useful as anti-inflammatory agents |
| 03/03/2004 | EP1392658A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| 03/03/2004 | EP1392657A2 Protease inhibitors |
| 03/03/2004 | EP1392656A2 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors |
| 03/03/2004 | EP1392655A2 Potassium channel openers |
| 03/03/2004 | EP1392651A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 03/03/2004 | EP1392648A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
| 03/03/2004 | EP1392645A2 Aza hydroxylated ethyl amine compounds |
| 03/03/2004 | EP1392644A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 03/03/2004 | EP1392643A2 Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| 03/03/2004 | EP1392642A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 03/03/2004 | EP1392641A1 Substituted cyclohexane-1,4-diamine derivatives |
| 03/03/2004 | EP1392375A2 Composition and use of substances for stabilising amino acids containing sulphur |
| 03/03/2004 | EP1392366A1 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 03/03/2004 | EP1392363A2 Compositions and uses of mglur5 antagonists |
| 03/03/2004 | EP1392355A1 Use of proteasome inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1392354A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 03/03/2004 | EP1392351A2 Chemokines as adjuvants of immune response |
| 03/03/2004 | EP1392347A2 Method of preventing cell death using segments of neural thread proteins |
| 03/03/2004 | EP1392345A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 03/03/2004 | EP1392344A1 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor |
| 03/03/2004 | EP1392329A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 03/03/2004 | EP1392326A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 03/03/2004 | EP1392324A1 Chemoprotection using amifostine and related compounds |